Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mitchell Waldran
Streptococcus pyogenes carriage is associated with distinct in vivo transcriptional states but not carrier-specific genotypes
STAR★Methods REAGENT or RESOURCESOURCEIDENTIFIER Bacterial and virus strains Group A Streptococcus clinical isolates This study Table 1 Group A Streptococcus NZ131 Lab strain/Reference N/A Biological samples Pediatric pharyngeal swab samples (acute pharyngitis and carrier follow-ups) Four pediatric clinics in Madison, WI, USA Protocol #2015–1456-CP016N/A Chemicals, peptides, and recombinant proteins Crystal violet (0.1% solution) Fisher Scientific Cat #B2193222 Hyaluronic acid (HA) standards...
Dengue virus structural proteins are expressed on the surface of DENV-infected cells and are a target for antibody-dependent cellular phagocytosis
Abstract Dengue virus (DENV) is an arboviral pathogen found in over 100 countries and a source of significant morbidity and mortality. While the mechanisms underpinning the pathophysiology of severe dengue are incompletely understood, it has been previously suggested that antibodies directed against the DENV envelope (E) protein can facilitate antibody dependent enhancement (ADE) of the infection, increasing the number of infected cells and the severity of infection in an exposed individual.
Antibody-dependent DENV infection induces distinct transcriptomic responses in infected and bystander human macrophages
Abstract Dengue virus (DENV) is a mosquito-borne flavivirus which coexists as four genetically and immunologically distinct serotypes (DENV1-4). In secondary heterologous DENV infection, pre-existing immunity is believed to contribute to severe disease through antibody dependent enhancement (ADE). Although the elevated pathology observed in ADE conditions has been described, the cell intrinsic mechanisms governing this process remain unclear.
Low-dose dengue virus 3 human challenge model: a phase 1 open-label study - Nature Microbiology
Abstract Dengue human infection models present an opportunity to explore the potential of a vaccine, anti-viral or immuno-compound for clinical benefit in a controlled setting. Here we report the outcome of a phase 1 open-label assessment of a low-dose dengue virus 3 (DENV-3) challenge model (NCT04298138), in which nine participants received a subcutaneous inoculation with 0.5 ml of a 1.4 × 103 plaque-forming unit per ml suspension of the attenuated DENV-3 strain CH53489.
DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection
Loading metrics Open Access Peer-reviewed Research Article ? This is an uncorrected proof. Citation: Wegman AD, Waldran MJ, Bahr LE, Lu JQ, Baxter KE, Thomas SJ, et al. (2023) DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection. PLoS Pathog 19(8): e1011616.
DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection
New Results doi: https://doi.org/10.1101/2023.04.01.535210 Abstract Dengue represents a growing public health burden worldwide, accounting for approximately 100 million symptomatic cases and tens of thousands of fatalities yearly. Prior infection with one serotype of dengue virus (DENV) is the greatest known risk factor for severe disease upon secondary infection with a heterologous serotype, a risk which increases as serotypes co-circulate in endemic regions.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mitchell
Contact Mitchell, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack